Intracranial Targeting of Cholesterol Processing Reveals a Therapeutic Vulnerability that Reprograms Glioblastoma and Promotes Antitumor Immunity

Zika virus oncolytic signaling reverts immunosuppressive and angiogenic glioblastoma microenvironment in vitro and in vivo

Glioblastoma (GBM), the most aggressive primary brain tumor, remains refractory to conventional therapies, characterized by high relapse rates and an extremely poor clinical prognosis. Oncolytic viruses represent a promising therapeutic frontier; specifically, Zika virus (ZIKV) has shown potent oncolytic activity again...

Natural and Synthetic Compounds, Swords for Glioblastoma Therapy: From Tumor to Its Microenvironment

Future studies should prioritize molecularly informed patient stratification, rational combination strategies, and advanced nanocarrier-mediated delivery platforms to facilitate the clinical translation of small-molecule therapeutics for GBM.

Natural Compounds Targeting Oncogenic Signaling Networks in Glioblastoma: Molecular Mechanisms, Translational Advances, and Clinical Perspectives

The use of molecular diagnostics, including biomarkers, genetic profiling, and advanced imaging, has significantly improved early identification and patient stratification, and the combination of natural compounds shows potential for creating safe, effective, and pathway‐specific treatments for GBM.

Macrophage-mesenchymal crosstalk in recurrent glioblastoma: a perspective for therapeutic strategies.

Glioblastoma (GBM) remains one of the most lethal cancers, with recurrence in nearly all patients despite standard therapy. However, the biological mechanisms governing recurrence remain incompletely understood. Increasing evidence suggests that recurrence is driven not only by tumor-intrinsic resistance, but also by d...

Breaking adaptive oncogenic resistance in glioblastoma via targeting the EGFR–STAT3 axis

Targeting NOTCH-immune crosstalk in gliomas: from mechanisms to therapeutics

Glioblastoma (GBM) is a highly aggressive and treatment-resistant malignancy characterized by an immunosuppressive tumor microenvironment (TME) that promotes disease progression and poor clinical outcomes. Increasing evidence suggests that NOTCH signaling is a key regulator of GBM progression, governing both tumor cell...